Virios Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 1.52 million compared to USD 3.96 million a year ago. Basic loss per share from continuing operations was USD 0.08 compared to USD 0.48 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3601 USD | +1.47% | -12.17% | -37.37% |
05-09 | Transcript : Virios Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
05-09 | Virios Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.37% | 6.83M | |
+5.07% | 109B | |
+11.60% | 105B | |
+0.12% | 22.25B | |
-12.22% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-9.86% | 16.85B | |
+4.75% | 13.76B | |
+34.95% | 12.46B |
- Stock Market
- Equities
- VIRI Stock
- News Virios Therapeutics, Inc.
- Virios Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023